Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets

The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis

(2010) A. M. Betts et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

On Setting the First Dose in Man: Quantitating Biotherapeutic Drug-Target Binding through Pharmacokinetic and Pharmacodynamic Models

(2009) Philip J. Lowe et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

(2009) Leonid Gibiansky et al.   Expert Opinion on Drug Metabolism & Toxicology

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

(2009) Helen J. Lachmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations

(2009) Hans Peter Grimm   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody

(2008) Wendy S. Putnam et al.   AAPS Journal

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients

(2008) A. Marathe et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Pharmacokinetic and Pharmacodynamic Modeling of a Humanized Anti-IL-13 Antibody in Naive and Ascaris-Challenged Cynomolgus Monkeys

(2008) Yulia Vugmeyster et al.   PHARMACEUTICAL RESEARCH